Ribozyme-mediated replacement of p53 RNA by targeted trans-splicing

Journal of Microbiology and Biotechnology

Volumn 12, Issue 5, 2002, Pages 844-848

  Shin, Kyung Sook ^b   Bae, Soo Jin ^a   Hwang, Eun Seong ^c   Jeong, Sunjoo ^a   Lee, Seong Wook ^a  

^a Dankook University   (South Korea)

^b Genoprot Inc   (South Korea)

^c University of Seoul   (South Korea)

Author keywords

Cancer; Gene therapy; p53; RNA replacement; Trans splicing ribozyme

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; RIB 40; RIB 96; RIBOZYME; RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DNA REPAIR; DRUG ACTIVITY; DRUG SYNTHESIS; DRUG USE; EXON; GENE ACTIVITY; GENE CONSTRUCT; GENE LIBRARY; GENE MAPPING; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE STRUCTURE; GENE TARGETING; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NONHUMAN; PHENOTYPE; REVERTANT; RNA SEQUENCE; SEQUENCE ANALYSIS; SEQUENCE TAGGED SITE; START CODON; TETRAHYMENA THERMOPHILA; TRANS SPLICING; TUMOR SUPPRESSOR GENE; WILD TYPE;

TETRAHYMENA THERMOPHILA;

EID: 0036826470     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Been, M. and T. Cech. 1986. One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. Cell 47: 207-216.
2. Chin, K. V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462.
3. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Paveltich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355.
4. Fearon, E. R. and B. Vogelstein. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
5. Harvey, M., H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L. A. Donehower. 1995. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9: 305-311.
6. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harri. 1991. p53 mutations in human cancers. Science 253: 49-53.
7. Hwang, S.-H., M.-W. Kim, S. K. Park, J. W. Noh, and I.-S. Han. 2001. Inhibition of gastric cancer cell cycle progression by γ-tubulin antisense oligonucleotides. J. Microbiol. Biotechnol. 10: 876-879.
8. Jones, J. T., S.-W. Lee, and B. A. Sullenger. 1996. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nature Med. 2: 643-648.
9. Jung, K.-E., M. Yang, K. Lee, H. Lim, J. Jung, B. Koo, L. S. Jeong, D.-H. Shin, C.-H. Lee, Y.-H. Cho, and Y. Lim. 2000. Structural study of antisense dimers, modified adenosine-thymidine phosphorothioate. J. Microbiol. Biotechnol. 10: 889-892.
10. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830.
11. Kim, M. J., J. Lee, and J. C. You. 2000. A new and rapid testing method for drug susceptibility of Mycobacterium leprae using RT-PCR. J. Microbiol. Biotechnol. 10: 685-689.
12. Kim, T.-W., S.-G. Min, D.-H. Choi, J.-S. Jo, and H.-Y. Kim. 2000. Rapid identification of Lactobacillus plantarum in Kimchi using polymerase chain reaction. J. Microbiol. Biotechnol. 10: 881-884.
13. Lan, N., R. P. Howrey, S.-W. Lee, C. A. Smith, and B. A. Sullenger. 1998. Ribozyme-mediated repair of sickle β-globin mRNA in erythrocyte precursors. Science 280: 1593-1596.
14. Lan, N., B. L. Rooney, S.-W. Lee, R. P. Howrey, C. A. Smith, and B. A. Sullenger. 2000. Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. Mol. Ther. 2: 245-255.
15. Lemoine, N. R. 1994. Molecular biology of breast cancer. Ann. Oncol. 5: S31-S37.
16. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
17. Lowe, S. W., S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E. Housman, and T. Jacks. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
18. Phylactou, L. A., C. Darrah, and M. A. J. Wood. 1998. Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat. Genet. 18: 378-381.
19. Roth, J. A., S. F. Grammer, S. G. Swisher, R. Komaki, J. Nemunaitis, J. Merritt, and R. E. Meyn. 2001. p53 gene replacement for cancer - interactions with DNA damaging agents. Acta Oncol. 40: 739-444.
20. Seo, H.-S. and S.-W. Lee. 2000. In vitro selection of the 2-fluoro-2-deoxyribonucleotide decoy RNA inhibitor of myasthenic autoantibodies. J. Microbiol. Biotechnol. 10: 707-713.
21. Sullenger, B. A. and T. R. Cech. 1994. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature 317: 619-622.
22. Sullenger, B. A. and T. R. Cech. 1995. RNA repair: A new possibility for gene therapy. J. NIH Res. 7: 46-47.
23. Tyner, S. D., S. Venkatachalam, J. Choi, S. Jones, N. Ghebranious, H. Igelmann, X. Lu, G. Soron, B. Cooper, C. Brayton, H. S. Park, T. Thompson, G. Karsenty, A. Bradley, and L. A. Donehower. 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53.
24. Watanabe, T. and B. A. Sullenger. 2000. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc. Natl. Acad. Sci. USA 97: 8490-8494.
25. Woodworth, C. D., H. Wang, S. Simpson, L. M. Alvarez-Salas, and V. Notario. 1993. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ. 4: 367-376.